Company Description
EMulate Therapeutics is on a mission to advance the development and adoption of medical, health, and environmental applications of our low-to-ultra-low radio frequency energy technology that are determined by the FDA (or other applicable regulators) to be non-toxic, non-invasive, non-ionizing, safe and effective.
We have invented and patented what we believe to be a groundbreaking technology that utilizes radio frequency energy (RFE) precisely targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to specifically regulate signaling and metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive therapeutic system.
Our device has been used in feasibility studies (phase 1 and phase 2 trials) to treat patients with GBM and DMG cancers, and will, consistent with FDA regulation, be used in pivotal clinical trials to treat GBM and DMG patients.
These uses are the first of many product expressions of the Company’s underlying ulRFE platform technology.
Our therapeutic medical device has potential treatment applications in a wide range of diseases, including cancer, acute and chronic pain management, mental health conditions, among others.
We expect that, for regulatory purposes, the EMulate Therapeutics ulRFE® therapeutic system will be evaluated by the FDA as a Class III medical device requiring approval of a PMA.
| Country | United States |
| Founded | 2002 |
| Industry | Health Care |
| Sector | Health Care Equipment & Supplies |
| Employees | 7 |
| CEO | Chris Rivera |
Contact Details
Address: 13810 SE Eastgate Way, Suite 560 Bellevue, WA 98005 United States | |
| Phone | (425) 415-3140 |
| Website | emulatetx.com |
Stock Details
| Ticker Symbol | EMTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001254348 |
| Employer ID | 91-2174500 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Chris E. Rivera | President, Chief Executive Officer and Chairman of the Board |
| Steven Pope | Corporate Secretary and Sr. VP, General Counsel |
| Kyle Kingma | Principal Financial and Accounting Officer |
| Bennett M. (Mike) Butters | Director |
| Andrew Daniels | Director |
| Richard Henriques | Director |
| John Kingma | Director |
| Charles E. McNerney | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2024 | RW | Filing |
| Sep 29, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 6, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 10, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 26, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 4, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 27, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 16, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 1, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 6, 2022 | DRS | [Cover] Draft Registration Statement |